Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 138

1.

Activation of mammalian target of rapamycin signaling pathway markers in minute adenocarcinoma of the prostate.

Faraj SF, Albadine R, Chaux A, Gonzalez-Roibon N, Hicks J, Humphreys E, Partin A, Netto GJ.

Urology. 2013 Nov;82(5):1083-9. doi: 10.1016/j.urology.2013.07.028. Epub 2013 Sep 11.

PMID:
24035134
2.

Dysregulation of mammalian target of rapamycin pathway in upper tract urothelial carcinoma.

Munari E, Fujita K, Faraj S, Chaux A, Gonzalez-Roibon N, Hicks J, Meeker A, Nonomura N, Netto GJ.

Hum Pathol. 2013 Dec;44(12):2668-76. doi: 10.1016/j.humpath.2013.07.008. Epub 2013 Sep 27.

PMID:
24074531
4.

Activation of the mammalian target of rapamycin signalling pathway in prostate cancer and its association with patient clinicopathological characteristics.

Dai B, Kong YY, Ye DW, Ma CG, Zhou X, Yao XD.

BJU Int. 2009 Oct;104(7):1009-16. doi: 10.1111/j.1464-410X.2009.08538.x. Epub 2009 Apr 15.

5.

Pharmacogenomic profiling of the PI3K/PTEN-AKT-mTOR pathway in common human tumors.

Xu G, Zhang W, Bertram P, Zheng XF, McLeod H.

Int J Oncol. 2004 Apr;24(4):893-900.

PMID:
15010827
6.

Expression status and prognostic significance of mammalian target of rapamycin pathway members in urothelial carcinoma of urinary bladder after cystectomy.

Schultz L, Albadine R, Hicks J, Jadallah S, DeMarzo AM, Chen YB, Nielsen ME, Gonzalgo ML, Sidransky D, Schoenberg M, Netto GJ.

Cancer. 2010 Dec 1;116(23):5517-26. doi: 10.1002/cncr.25502. Epub 2010 Oct 11. Erratum in: Cancer. 2011 Nov 1;117(21):5021. Neilsen, Matthew E [corrected to Nielsen, Matthew E].

7.

Immunoexpression status and prognostic value of mTOR and hypoxia-induced pathway members in primary and metastatic clear cell renal cell carcinomas.

Schultz L, Chaux A, Albadine R, Hicks J, Kim JJ, De Marzo AM, Allaf ME, Carducci MA, Rodriguez R, Hammers HJ, Argani P, Reuter VE, Netto GJ.

Am J Surg Pathol. 2011 Oct;35(10):1549-56. doi: 10.1097/PAS.0b013e31822895e5.

8.

A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features.

Trigka EA, Levidou G, Saetta AA, Chatziandreou I, Tomos P, Thalassinos N, Anastasiou N, Spartalis E, Kavantzas N, Patsouris E, Korkolopoulou P.

Oncol Rep. 2013 Aug;30(2):623-36. doi: 10.3892/or.2013.2512. Epub 2013 May 31.

PMID:
23728071
9.

Dysregulation of mammalian target of rapamycin pathway in plasmacytoid variant of urothelial carcinoma of the urinary bladder.

Gonzalez-Roibon ND, Chaux A, Al-Hussain T, Osunkoya AO, Bezerra SM, Hicks J, Epstein JI, Netto GJ.

Hum Pathol. 2013 Apr;44(4):612-22. doi: 10.1016/j.humpath.2012.07.009. Epub 2012 Oct 17.

10.

Expression of the mammalian target of rapamycin pathway markers in lung adenocarcinoma and squamous cell carcinoma.

Kim HS, Kim GY, Lim SJ, Kim YW.

Pathobiology. 2012;79(2):84-93. doi: 10.1159/000334340. Epub 2012 Jan 27.

PMID:
22286903
11.

Expression of mTOR signaling pathway markers in prostate cancer progression.

Kremer CL, Klein RR, Mendelson J, Browne W, Samadzedeh LK, Vanpatten K, Highstrom L, Pestano GA, Nagle RB.

Prostate. 2006 Aug 1;66(11):1203-12.

PMID:
16652388
12.

Activation of PI3K/Akt/mTOR signaling pathway triggered by PTEN downregulation in the pathogenesis of Crohn's disease.

Long SH, He Y, Chen MH, Cao K, Chen YJ, Chen BL, Mao R, Zhang SH, Zhu ZH, Zeng ZR, Hu PJ.

J Dig Dis. 2013 Dec;14(12):662-9. doi: 10.1111/1751-2980.12095.

PMID:
23962154
13.

Dysregulation of the mammalian target of rapamycin pathway in chromophobe renal cell carcinomas.

Chaux A, Albadine R, Schultz L, Hicks J, Carducci MA, Argani P, Allaf M, Netto GJ.

Hum Pathol. 2013 Oct;44(10):2323-30. doi: 10.1016/j.humpath.2013.05.014. Epub 2013 Aug 15.

PMID:
23953228
14.

PTEN deficiency is fully penetrant for prostate adenocarcinoma in C57BL/6 mice via mTOR-dependent growth.

Blando J, Portis M, Benavides F, Alexander A, Mills G, Dave B, Conti CJ, Kim J, Walker CL.

Am J Pathol. 2009 May;174(5):1869-79. doi: 10.2353/ajpath.2009.080055.

15.

Expression of molecular markers associated with the mammalian target of rapamycin pathway in nonmetastatic renal cell carcinoma: Effect on prognostic outcomes following radical nephrectomy.

Nishikawa M, Miyake H, Harada K, Fujisawa M.

Urol Oncol. 2014 Jan;32(1):49.e15-21. doi: 10.1016/j.urolonc.2013.07.014. Epub 2013 Nov 13.

PMID:
24239474
16.

The Akt/mammalian target of rapamycin pathway is activated and associated with adverse prognosis in soft tissue leiomyosarcomas.

Setsu N, Yamamoto H, Kohashi K, Endo M, Matsuda S, Yokoyama R, Nishiyama K, Iwamoto Y, Dobashi Y, Oda Y.

Cancer. 2012 Mar 15;118(6):1637-48. doi: 10.1002/cncr.26448. Epub 2011 Aug 11.

17.

An immunohistochemical signature comprising PTEN, MYC, and Ki67 predicts progression in prostate cancer patients receiving adjuvant docetaxel after prostatectomy.

Antonarakis ES, Keizman D, Zhang Z, Gurel B, Lotan TL, Hicks JL, Fedor HL, Carducci MA, De Marzo AM, Eisenberger MA.

Cancer. 2012 Dec 15;118(24):6063-71. doi: 10.1002/cncr.27689. Epub 2012 Jun 6.

18.

Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers.

Zhou X, Tan M, Stone Hawthorne V, Klos KS, Lan KH, Yang Y, Yang W, Smith TL, Shi D, Yu D.

Clin Cancer Res. 2004 Oct 15;10(20):6779-88.

19.
20.

Expression of PTEN and mTOR in pancreatic neuroendocrine tumors.

Han X, Ji Y, Zhao J, Xu X, Lou W.

Tumour Biol. 2013 Oct;34(5):2871-9. doi: 10.1007/s13277-013-0849-1. Epub 2013 May 19.

PMID:
23686804
Items per page

Supplemental Content

Write to the Help Desk